{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:01:43Z","timestamp":1790776903551,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n Hepatic steatosis is an increasingly important liver\u2010related comorbidity among people with HIV. We evaluated longitudinal changes in hepatic steatosis over 8\u2009years and the associated clinical factors in a single\u2010centre Japanese cohort of people with HIV.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This single\u2010centre retrospective cohort study included 94 people with HIV who underwent paired FibroScan assessments a median of 8.18\u2009years apart. Hepatic steatosis was defined as a controlled attenuation parameter (CAP) \u2265238\u2009dB\/m, with incident steatosis defined as CAP <\u2009238\u2009dB\/m at baseline and CAP \u2265238\u2009dB\/m at follow\u2010up. Factors associated with incident steatosis and follow\u2010up CAP were assessed using Firth's penalized logistic regression and an analysis of covariance (ANCOVA)\u2010type multivariable linear model, respectively.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Median CAP increased from 232 to 282\u2009dB\/m (\n p<\/jats:italic>\n \u2009<\u20090.001), while the prevalence of hepatic steatosis increased from 45\/94 (48%) to 63\/94 (67%) (\n p<\/jats:italic>\n \u2009=\u20090.001). Of 49 participants without baseline steatosis, 24 (49%) developed incident steatosis. After adjustment for baseline CAP, greater percentage weight gain, higher baseline body mass index and triglycerides \u2265200\u2009mg\/dL at follow\u2010up were each associated with higher follow\u2010up CAP, whereas tenofovir alafenamide (TAF) exposure during follow\u2010up was not. Median liver stiffness measurement (LSM) did not change significantly.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n CAP values and the prevalence of hepatic steatosis increased over 8\u2009years in this single\u2010centre Japanese cohort of people with HIV. Greater weight gain and metabolic abnormalities were associated with higher CAP at follow\u2010up. These observational findings suggest that monitoring body weight, metabolic parameters, hepatic steatosis and liver stiffness may be useful in long\u2010term HIV care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/hiv.70312","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:40:50Z","timestamp":1790775650000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eight\u2010year changes in hepatic steatosis and associated metabolic factors in a Japanese cohort of people with\n HIV<\/scp>"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-5030","authenticated-orcid":false,"given":"Masayuki","family":"Murata","sequence":"first","affiliation":[{"name":"Department of Environmental Medicine and Infectious Diseases, Faculty of Medical Sciences Kyushu University Fukuoka Japan"},{"name":"Department of General Internal Medicine Kyushu University Hospital Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0190-6184","authenticated-orcid":false,"given":"Yuji","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Environmental Medicine and Infectious Diseases, Faculty of Medical Sciences Kyushu University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine Kyushu University Hospital Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-7659","authenticated-orcid":false,"given":"Sho","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Environmental Medicine and Infectious Diseases, Faculty of Medical Sciences Kyushu University Fukuoka Japan"},{"name":"Department of General Internal Medicine Kyushu University Hospital Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine Kyushu University Hospital Fukuoka Japan"},{"name":"Department of Environmental Medicine and Infectious Diseases, Graduate School of Medical Sciences Kyushu University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine Kyushu University Hospital Fukuoka Japan"},{"name":"Department of Environmental Medicine and Infectious Diseases, Graduate School of Medical Sciences Kyushu University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction\u2010associated steatotic liver disease","volume":"393","author":"Targher G","year":"2025","journal-title":"N Engl J Med"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2010EASD\u2010EASO clinical practice guidelines on the management of metabolic dysfunction\u2010associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2024","journal-title":"J Hepatol"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella ME","year":"2023","journal-title":"Hepatology"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/QAD.0000000000001504","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in HIV\u2010monoinfection","volume":"31","author":"Maurice JB","year":"2017","journal-title":"Aids"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.2147\/IJGM.S528870","article-title":"Pathogenesis of HIV\u2010associated metabolic syndrome and clinical management recommendations","volume":"18","author":"Ge L","year":"2025","journal-title":"Int J Gen Med"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cgh.2023.01.001","article-title":"Prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV monoinfection: a systematic review and meta\u2010analysis","volume":"21","author":"Kalligeros M","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/589294","article-title":"Nonalcoholic fatty liver disease in HIV\u2010infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors","volume":"47","author":"Guaraldi G","year":"2008","journal-title":"Clin Infect Dis"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/QAD.0000000000000248","article-title":"Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV\u2010infected patients","volume":"28","author":"Mac\u00edas J","year":"2014","journal-title":"Aids"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta\u2010analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas T","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes PJ","year":"2019","journal-title":"Gastroenterology"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101116","article-title":"Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy","volume":"40","author":"Bischoff J","year":"2021","journal-title":"EClinicalMedicine"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non\u2010obese or lean non\u2010alcoholic fatty liver disease: a systematic review and meta\u2010analysis","volume":"5","author":"Ye Q","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body\u2010mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"WHO Expert Consultation","year":"2004","journal-title":"Lancet"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","article-title":"Controlled attenuation parameter (CAP): a novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes","volume":"36","author":"Sasso M","year":"2010","journal-title":"Ultrasound Med Biol"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong VWS","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling RK","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan\u2010AST (FAST) score for the non\u2010invasive identification of patients with non\u2010alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome PN","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A solution to the problem of separation in logistic regression","volume":"21","author":"Heinze G","year":"2002","journal-title":"Stat Med"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/hepr.13947","article-title":"Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: a large\u2010scale multicenter retrospective study","volume":"53","author":"Fujii H","year":"2023","journal-title":"Hepatol Res"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12072-021-10143-4","article-title":"The epidemiology of NAFLD and lean NAFLD in Japan: a meta\u2010analysis with individual and forecasting analysis, 1995\u20132040","volume":"15","author":"Ito T","year":"2021","journal-title":"Hepatol Int"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1111\/liv.15055","article-title":"Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008\u20132019","volume":"41","author":"Sugiyama A","year":"2021","journal-title":"Liver Int"},{"key":"e_1_2_12_23_1","unstructured":"National Institute of Health and Nutrition National Institutes of Biomedical Innovation Health and Nutrition.The National Health and Nutrition Survey (NHNS) Japan 2019: summary. Based on the report of the Ministry of Health Labour and Welfare Japan.https:\/\/www.nibn.go.jp\/eiken\/kenkounippon21\/download_files\/eiyouchousa\/2019.pdf. Accessed August 7 2026.2021."},{"key":"e_1_2_12_24_1","unstructured":"Ministry of Health Labour and Welfare Japan.The National Health and Nutrition Survey in Japan 2023: summary of results [in Japanese]. Tokyo: Ministry of Health Labour and Welfare.2024.https:\/\/www.mhlw.go.jp\/content\/10900000\/001338334.pdf. Accessed September 8 2026."},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/QAD.0000000000004419","article-title":"Risk factors of metabolic dysfunction\u2010associated fatty liver disease in people with HIV receiving antiretroviral therapy","volume":"40","author":"Yuan R","year":"2026","journal-title":"Aids"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax PE","year":"2020","journal-title":"Clin Infect Dis"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter WDF","year":"2019","journal-title":"N Engl J Med"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a U.S. cohort study","volume":"24","author":"Mallon PWG","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jiac.2022.10.014","article-title":"Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV","volume":"29","author":"Sekiya R","year":"2023","journal-title":"J Infect Chemother"},{"key":"e_1_2_12_30_1","first-page":"990","article-title":"Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide in people with HIV","volume":"79","author":"Damas J","year":"2024","journal-title":"Clin Infect Dis"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long\u2010term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo P","year":"2015","journal-title":"Gastroenterology"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/hiv.70079","article-title":"Metabolic dysfunction\u2010associated liver disease predicts incident liver fibrosis in people with HIV mono\u2010infection: a cohort study","volume":"26","author":"Fittipaldi J","year":"2025","journal-title":"HIV Med"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70312","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70312","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:40:54Z","timestamp":1790775654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":31,"alternative-id":["10.1111\/hiv.70312"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70312","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2026-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hiv.70312"}}